WVE - Wave Life Sciences GAAP EPS of -$0.47 misses by $0.06 revenue of $1.24M misses by $1.16M
2023-03-22 07:40:49 ET
- Wave Life Sciences press release ( NASDAQ: WVE ): Q4 GAAP EPS of -$0.47 misses by $0.06 .
- Revenue of $1.24M (-29.5% Y/Y) misses by $1.16M .
- As of December 31, 2022, Wave had $88.5 million in cash and cash equivalents, as compared to $150.6 million as of December 31, 2021. As previously disclosed, Wave entered into a strategic collaboration with GSK that became effective in the first quarter of 2023 and provided upfront cash of $170 million to Wave.
- Accordingly, the Company expects that its current cash and cash equivalents will be sufficient to fund operations into 2025.
For further details see:
Wave Life Sciences GAAP EPS of -$0.47 misses by $0.06, revenue of $1.24M misses by $1.16M